Relief Therapeutics (Switzerland) Today
| RLF Stock | CHF 2.26 0.11 4.64% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Relief Therapeutics is selling for under 2.26 as of the 25th of March 2025; that is 4.64 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.26. Relief Therapeutics has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. The company has 4.39 B outstanding shares. More on Relief Therapeutics Holding
Moving together with Relief Stock
Moving against Relief Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Relief Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Relief Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Relief Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Relief Therapeutics Holding (RLF) is traded on SIX Swiss Exchange in Switzerland and employs 10 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 114.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Relief Therapeutics's market, we take the total number of its shares issued and multiply it by Relief Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Relief Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 4.39 B outstanding shares.
Relief Therapeutics Holding has accumulated about 29.87 M in cash with (35.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Relief Therapeutics Probability Of Bankruptcy
Ownership AllocationRelief Therapeutics owns a total of 4.39 Billion outstanding shares. Relief Therapeutics holds 3.68 pct. of its outstanding shares held by insiders and 22.16 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Relief Ownership Details
Relief Therapeutics Risk Profiles
Although Relief Therapeutics' alpha and beta are two of the key measurements used to evaluate Relief Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.45 | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.24 | |||
| Risk Adjusted Performance | (0.13) |
Relief Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Relief Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Relief Therapeutics Corporate Management
Elected by the shareholders, the Relief Therapeutics' board of directors comprises two types of representatives: Relief Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Relief. The board's role is to monitor Relief Therapeutics' management team and ensure that shareholders' interests are well served. Relief Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Relief Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeremy CPA | CFO Officer | Profile | |
| David McCullough | Sr Access | Profile | |
| DPhil MBA | Chief Officer | Profile | |
| Jeremy Meinen | Chief Admin | Profile | |
| Dorian Bevec | Chief Lifescience | Profile | |
| Drew CroninFine | Exec Marketing | Profile | |
| Christopher Wick | Sr Sales | Profile |
Additional Tools for Relief Stock Analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.